Member resources
Topic-specific groups in several research areas are among the key tools and resources being established to facilitate clinical research in low-resource settings.
Working groups, advisory groups and support groups consist of experts that are working together on specific research areas to support CERCLE members and others conducting clinical research on infectious diseases of epidemic and pandemic potential, including COVID-19, as well as AMR.
The group members gather solutions, tools, documents, and advice on the website. All resources are also made available on dedicated project pages.
Browse resources
| Name | Type of resource | Research area / Working Group | Description (Optional) | Language | Attachments | URL |
|---|---|---|---|---|---|---|
| IECS Institute for Clinical Effectiveness and Health Policy | Website | Clinical Epidemiology | On this website you will find tools to facilitate navigation among the mass of data on COVID-19 generated on a daily basis. IECS provides access to health technology assessment (HTA) documents on pandemic-related interventions. It has selected access addresses to organizations and institutions that offer reliable information for decision making related to the pandemic and are an essential reference for decision makers, researchers, health professionals and anyone interested. Key parameters are available in COVID models, evidence that was obtained through an exhaustive review of the scientific literature. They have also developed an interactive tool to assess the impact of the pandemic on health systems in Latin America and the Caribbean and make available videos of webinars on COVID-19. Translated with www.DeepL.com/Translator (free version) | Spanish | https://www.iecs.org.ar/covid/ | |
| Challenges in conducting clinical research in resource-limited settings: Experiences during COVID-19 | Webinar / Workshop recording | Clinical Epidemiology | In this webinar, experts and members of the Clinical Epidemiology Working Group of the COVID-19 Clinical Research Coalition will give a brief overview of the response to the COVID-19 pandemic from resource-limited settings. As expected, these challenges can be very broad, and therefore, the presenters will use different region-specific examples as a vehicle to expose those challenges focusing on resources, logistics, and cultural barriers. This webinar will aid the scientific community to gain a general perspective of the challenges that fellow researchers from resource-limited settings have encountered during the COVID-19 pandemic, to guide more equitable decision-making processes in this current pandemic and future outbreaks. | English | https://covid19crc.org/videos/2021/challenges-conducting-clinical-research-resource-limited-settings-experiences-during-covid19/ | |
| Recados – Unidad de Síntesis y Transferencia de Conocimiento | Website | Clinical Epidemiology | Errands - Synthesis and Knowledge Transfer Unit Learn about the most relevant knowledge advances related to COVID-19 produced globally. | Spanish | https://www.cardioinfantil.org/recados-unidad-sintesis-transferencia/ | |
| COVID-19 Clinical management: living guidance | Guidance | Clinical Management of COVID-19 in Resource-limited Settings | The WHO COVID-19 Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is important. | English | WHO-2019-nCoV-clinical-2021_1-eng.pdf (https://v5.airtableusercontent.com/v3/u/49/49/1767859200000/OJyB1Fdru5q-kd21E9Sb5w/4s9_V7QmsY-BpVfM8Pv7v8nbpXOS51a6zB4BetnfBMgsBYPO_GFpu5M7zPio5CAqaJ6gP7LfV63lUsadl7RHgp-T4we9pbJUzsJ-vHjatlTVpziji6HuGJ3ncH6mJrraRHYezaGC0tY9svHvBNV_B-N-Bu11zINOYwWO9EASDKrk1tFFsRGdMZ_k9rn7agme/Q2BZCz3swTHhyEqs3VYH5nhhLZWzJmapy0nU934q9lE) | https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 |
| Clinical management of patients with COVID-19: Rehabilitation of patients with COVID-19 | Course / Training | Clinical Management of COVID-19 in Resource-limited Settings | The course of the Clinical Management of Patients with COVID-19 course series is devoted to the rehabilitation of patients with COVID-19. The seven course modules address the manifold and varied rehabilitation needs of patients recovering from COVID-19, including patients with cognitive impairment, physical deconditioning and weakness, respiratory impairment, swallow impairment, communication impairment and challenges in completing Activities of Daily Living (ADLs). Techniques for rehabilitation also are addressed. | English,Macedonian,Russian,Chinese,Albanian | https://openwho.org/courses/clinical-management-COVID-19-rehabilitation | |
| Traditional medicine and COVID-19 scientific research | Video | Clinical Pharmacology and Drug Candidates | Spanish,English,Portuguese | https://www.youtube.com/watch?v=6YOz75CJ9us | ||
| IDDO guidance for blood pharmacokinetic sample collection, processing and transport in COVID-19 clinical trials | Guidance | Clinical Pharmacology and Drug Candidates | This procedure describes the process for taking pharmacokinetic (PK) samples from the phlebotomist to processing in an interim processing (e.g. ward) laboratory and onto an analytical laboratory in clinical trials. | English | https://www.iddo.org/document/blood-pharmacokinetic-sample-collection-processing-and-transport-covid-19-clinical-trials | |
| Collection of ECG data in COVID-19 clinical trials | Guidance | Clinical Pharmacology and Drug Candidates | This document provides guidance for a general process for collecting the standard 12-lead clinical trial ECG data, to support any trial-specific instructions. It does not include ambulatory (e.g. Holter) ECGs. The document, which is not prescriptive, may be adapted by sites as required. | English | https://www.iddo.org/document/collection-ecg-data-covid-19-clinical-trials | |
| COVID-19 Pharmacology Resource Center | Website | Clinical Pharmacology and Drug Candidates | It Includes an in silico workbench, outcomes database, and clinical trial tracker | English | https://www.covidpharmacology.com/ | |
| University of Liverpool Covid19 Drug Interactions website | Website | Clinical Pharmacology and Drug Candidates | A freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medication | English | https://www.covid19-druginteractions.org/ | |
| Controlled Human Infection Challenge Studies: Lessons from Malaria towards COVID-19 | Webinar / Workshop recording | Clinical Pharmacology and Drug Candidates | Controlled Human Infection Challenge Studies involve the deliberate infection of healthy volunteers to support clinical vaccine development, for example for malaria. This webinar will discuss ethical and scientific principles for such studies, outline the risk mitigation steps taken in previous malaria human challenge studies, explore how this might be applied in the context of COVID-19 vaccine development, and address ethical and practical concerns. | English | https://covid19crc.org/event/controlled-human-infection-challenge-studies-lessons-from-malaria-towards-covid-19/# | |
| Model-informed Drug Repurposing - Applications for COVID-19 | Webinar / Workshop recording | Clinical Pharmacology and Drug Candidates | During the webinar hosted by Adeniyi Olagunju, we covered the importance of integrating clinical pharmacology and translational medicine principles in COVID-19 dosing strategy and study design. Following this, Michael Dodds, Samer Mouksassi and Yuan Xiong from Certara demonstrated the pharmacokinetic pharmacodynamic (PKPD) simulation tools available on covidpharmacology.com using recently completed analyses for ivermectin, chloroquine, and lopinavir/ritonavir. | English | https://www.pmxafrica.org/post/webinar-recap-model-informed-drug-repurposing-applications-for-covid-19 | |
| What are the existing gaps in knowledge and skills among researchers in low- and middle-income countries, to effectively share and use COVID-19 research data? | Webinar / Workshop recording | Data Sharing | Online Workshop on the existing gaps in knowledge and skills among researchers in low- and middle-income countries, to effectively share and use COVID-19 research data | English | https://covid19crc.org/event/online-workshop-what-are-the-existing-gaps-in-knowledge-and-skills-among-researchers-in-low-and-middle-income-countries-to-effectively-share-and-use-covid-19-research-data/ | |
| Data Sharing | Course / Training | Data Sharing | Expectation from health research funders, regulatory agencies, and journals for sharing of de-identified individual-level health research data is now increasing. Arguments in favour of data sharing include maximising the utility of the data, improving research transparency and allowing confirmation of the interpretation of results, with the overall goal of improving science and health. However, the volume of data shared remains low. This has been partially attributed to lack of data management capacity and lack of knowledge of how and where to share data. This course aims to fill this gap by giving you basic and practical guidance in data management and sharing. Each module has been written by an author/authors expert in the subject matter and has been peer-reviewed. | English | https://globalhealthtrainingcentre.tghn.org/data-sharing/ | |
| Ethics and data sharing resources | Website | Data Sharing | The Global Health Network is gathering links to collections of resources to support the development of data sharing policies and processes. Policies and Guidance - for sharing clinical, genetic and public health research data from research funders, regulatory agencies and journals Reports - about best practices in sharing individual-level human research data from a range of sources Articles - from peer reviewed journals discussing ethical and policy aspects of sharing individual-level data from clinical and public health research Platforms and Governance - for sharing clinical, genetic, social science and public health research data or supporting data curation and sharing. | English | https://globalhealthbioethics.tghn.org/ethics-and-data-sharing-resources/ | |
| Research in Global Health Emergencies | Report / Publication | Data Sharing | See chapter 9 on data sharing You can download the full report, short report and overview of the report in the left-hand navigation on this page. The overview and short version are available in Chinese, Farsi and French and the overview in Arabic, Portuguese and Spanish - see the translation page. You can also read the short report online. | English | https://www.nuffieldbioethics.org/publications/research-in-global-health-emergencies | |
| RDA COVID-19 Recommendations and Guidelines for Data Sharing | Guidance | Data Sharing | The Research Data Alliance (RDA) COVID-19 Working Group members bring various, global expertise to develop a body of work that comprises how data from multiple disciplines inform response to a pandemic combined with guidelines and recommendations on data sharing under the present COVID-19 cicumstances. This extends to research software sharing, in recognition of the key role in software in analysing data. The work has been divided into four research areas (namely, clinical, omics, epidemiology, social sciences) with four cross cutting themes (namely, community participation, indigenous data, legal and ethical considerations, research software), as a way to focus the conversations, and provide an initial set of guidelines in a tight timeframe. The detailed guidelines are aimed to help stakeholders follow best practices to maximise the efficiency of their work, and to act as a blueprint for future emergencies. The recommendations in the document are aimed at helping policymakers and funders to maximise timely, quality data sharing and appropriate responses in such health emergencies. | English | https://rd-alliance.org/group/rda-covid19-rda-covid19-omics-rda-covid-19-epidemiology-rda-covid19-clinical-rda-covid19-0 | |
| GloPID-R data sharing resources | Website | Data Sharing | English | https://www.glopid-r.org/our-work/data-sharing/ | ||
| Vivli clinical data sharing platform | Website | Data Sharing | Vivli clinical data sharing platform (free for COVID-19 data and LMIC-based researchers) | English | https://vivli.org/ | |
| Public Health Emergency Preparedness and Response Ethics Network (PHEPREN) | Website | Ethics | Led by the World Health Organization and supported by key partners including the Fogarty International Center, Global Forum on Bioethics in Research, Global Health Network, Global Network of WHO Collaborating Centres and Wellcome, Epidemic Ethics is a global community of bioethicists building on pre-existing expertise and resources to provide real-time, trusted, contextual support to communities, policy makers, researchers, and responders in relation to the ethical issues arising out of global health emergencies, with a current focus on the COVID-19 pandemic. | English | https://epidemicethics.tghn.org/ | |
| Research in global health emergencies: Ethical issues by the Nuffield Council on Bioethics | Report / Publication | Ethics | English | Nuffield-ResearchinGlobalHealthEmergencies-2020.pdf (https://v5.airtableusercontent.com/v3/u/49/49/1767859200000/JHk8DVkdVBPq5ejZ15JhPw/49c8Ym7lGYbwD0N0T7qZlh8qx2dsUr726XQTJsfDJR1XiVzCGteQhrOO_Qaikjj1FuaaMQYb0xZNu-6tzN3p3Rc_mHkDwN8GvwPfsy3bchP5HjvA-G2ER_nQmrBEglEHnZqQd9ZSAVtmTykvPHhoxlSneaOC1WTHqJRQqa_0e0ilB7agp075-SNV01obCdPn/ctMYuOfKnbrf5UuiHm0xNeW2oFZSESGryydvbl3YbDw) | https://covid19crc.org/wp-content/uploads/2020/09/Nuffield-ResearchinGlobalHealthEmergencies-2020.pdf | |
| Importance of Ethics When Conducting Research on COVID-19 | Video | Ethics | Dr Aissatou Touré, Director of Alliance pour la Recherche et l'Ethique en Afrique (ARE Africa), is a member of the Ethics Working Group of the COVID-19 Clinical Research Coalition. In this interview, she discusses why the issues of ethics is essential for #COVID19 research. | French,English | https://www.youtube.com/watch?v=wm2ok-x-vfc | |
| Johns Hopkins University Center for Humanitarian Health – Maternal and child health, Nutrition and COVID-19 scientific repository | Website | "Maternal, Newborn and Child Health" | This repository was compiled by the Johns Hopkins Center for Humanitarian Health and provides an overview of research on COVID-19, maternal and child health (including infants), and nutrition. This repository includes scientific publications from 1 February 2020 - 30 April 2021. | English | http://hopkinshumanitarianhealth.org/empower/advocacy/covid-19/covid-19-children-and-nutrition/ | |
| Evaluation and Management Considerations for Neonates At Risk for COVID-19 - US CDC | Guidance | "Maternal, Newborn and Child Health" | This guidance is intended to inform healthcare providers in the United States about the diagnosis, evaluation, infection prevention and control practices, and disposition of neonates (≤28 days old) with suspected or confirmed SARS-CoV-2 infection or known SARS-CoV-2 exposure, including birth to a mother with suspected or confirmed COVID-19. | English | https://www.cdc.gov/coronavirus/2019-ncov/hcp/caring-for-newborns.html | |
| Data on COVID-19 during Pregnancy: Birth and Infant Outcomes - US CDC | Website | "Maternal, Newborn and Child Health" | Health departments report information on cases of COVID-19 to CDC, including pregnancy status. State and local health departments have the option of providing additional data on pregnant women with COVID-19 and their infants, which are collected as part of CDC’s Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET). 25 jurisdictions are currently reporting data. | English | https://covid.cdc.gov/covid-data-tracker/?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fspecial-populations%2Fbirth-data-on-covid-19.html#pregnant-birth-infant | |
| Data on COVID-19 during pregnancy : Severity of maternal illness - US CDC | Website | "Maternal, Newborn and Child Health" | English | https://stacks.cdc.gov/view/cdc/98863 | ||
| COVID-19 Resources - FIGO | Website | "Maternal, Newborn and Child Health" | Wide array of internationally relevant resources relating to COVID-19 and sexual, reproductive and maternal health provided by the International Federation of Gynecology and Obstetrics (FIGO). Their statements on COVID-19 In Low-Middle-Income Countries are available in English and French | English | https://www.figo.org/resources/covid-19-resources | |
| COVID-19 Data Collection - FIGO | Website | "Maternal, Newborn and Child Health" | Information about studies and pregnancy registries which are currently collecting information about COVID-19 during pregnancy and the postnatal period provided by the International Federation of Gynecology and Obstetrics (FIGO). | English | https://www.figo.org/covid-19-data-collection-your-contribution-needed | |
| Ripe Tomato – COVID-19 in pregnancy | Website | "Maternal, Newborn and Child Health" | Personal blog run by Professor Jim Thornton (Professor of Obstetrics and Gynaecology at University of Nottingham). This comprehensive resource contains regularly updated scientific news reports, case reports, registries and studies relating to COVID-19 in pregnancy | English | https://ripe-tomato.org/2020/04/21/covid-19-pregnancy-navigation-page/ | |
| COVID-19 evidence alerts | Newsletter / Mailing list / email alert | "Maternal, Newborn and Child Health" | sign up to receive email alerts tailored to your specialty interests | English | https://plus.mcmaster.ca/COVID-19/ | |
| COVID-19 Resource Centre - the Lancet | Website,Report / Publication | Clinical Epidemiology,Clinical Management of COVID-19 in Resource-limited Settings,Clinical Pharmacology and Drug Candidates,Data Management,Data Sharing,Ethics,"Maternal, Newborn and Child Health",Regulatory,Social Science,Study Design and Analytics,Supply and Market Dynamics; Medicine Quality,"Virology, Immunology and Diagnostics",Vaccines,Therapeutics | Comprehensive resource containing all Lancet publications relating to COVID-19 | English | https://www.thelancet.com/coronavirus?dgcid=kr_pop-up_tlcoronavirus20 | |
| COVID-19 in Pregnancy (PregCOV-19LSR) | Systematic Review,Website | "Maternal, Newborn and Child Health" | We aim to undertake living systematic reviews (LSR) involving pregnant and postnatal women at risk, suspected, and diagnosed to have COVID-19, and synthesise the relevant evidence on prevalence, risk factors, mother-to-child transmission, diagnosis, treatment of the disease. The findings will be continuously updated, by incorporating appropriate new evidence as it becomes available. | English | https://www.birmingham.ac.uk/research/who-collaborating-centre/pregcov/index.aspx | |
| Royal College of Obstetricians and Gynaecologists (RCOG): Coronavirus in pregnancy | Website,Systematic Review,Guidance | "Maternal, Newborn and Child Health" | The impact of new evidence and changes in policy on the published guidance is reviewed on a weekly basis. Extensive literature review comprising international data relating to COVID-19 in pregnancy | English | https://www.rcog.org.uk/coronavirus-pregnancy | |
| Novel Coronavirus (COVID-19) Updates & Information - AWHONN | Website,Guidance | "Maternal, Newborn and Child Health" | AWHONN is committed to supporting nurses during the pandemic with updates on AWHONN’s efforts related to practice, advocacy, meetings, and organizational messages as well as general resources of interest and links to valuable self-care tools. This information is published in good faith and for general information purposes only. While we strive to provide quality links to useful and websites, we have no control over the content published by other organizations. | English | https://www.awhonn.org/novel-coronavirus-covid-19/ | |
| American College of Obstetricians and Gynecologists (ACOG) – COVID-19 FAQs | Website | "Maternal, Newborn and Child Health" | COVID-19 FAQ | English | https://www.acog.org/clinical-information/physician-faqs | |
| Society for Maternal and Fetal Medicine (SMFM): Coronavirus (COVID-19) | Website,Course / Training,Guidance,Report / Publication | "Maternal, Newborn and Child Health" | SMFM has developed resources to support the work of OB care providers and their patients during the global pandemic. SMFM members are also invited to join our new online community dedicated to COVID-19. Engage with other MFMs, share clinical cases and resources from your institution, and see what others are doing. | English | https://www.smfm.org/covid19 | |
| COVID-19 research priorities in maternal, reproductive, and child health | Webinar / Workshop recording | "Maternal, Newborn and Child Health" | The coalition’s Maternal, Newborn, and Child Health Working Group conducted a research priority-setting exercise between October 2020 and January 2021 to identify global research priorities in maternal, reproductive and child health. The working group shared the results in this webinar. | English | https://covid19crc.org/videos/2021/covid-19-research-priorities-in-maternal-reproductive-and-child-health/ | |
| FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency | Guidance | Regulatory | This guidance is being issued to address the Coronavirus Disease 2019 (COVID-19) public health emergency. This guidance is being implemented without prior public comment because the Food and Drug Administration (FDA or Agency) has determined that prior public participation for this guidance is not feasible or appropriate (see section 701(h)(1)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and 21 CFR 10.115(g)(2)). This guidance document is being implemented immediately, but it remains subject to comment in accordance with the Agency’s good guidance practices. | English | https://covid19crc.org/wp-content/uploads/2020/09/Regulatory_FDA_GuidanceCOVID19_2020.pdf | |
| AVAREF Guidance Emergency Preparedness May 2020 | Guidance | Regulatory | The purpose of this document is to guide and assist ethics committees (ECs) and national regulatory authorities (NRAs) to plan, undertake expedited reviews and approvals of clinical trial applications, and provide oversight of trials during a pandemic or epidemic. This strategy is consistent with national emergency preparedness and response plans for public health emergencies. It is also intended to inform and guide regulators and ethics committees of the Regional Economic Communities (RECs) in Africa and sponsors on the critical elements of emergency preparedness to ensure that ethics and regulatory decisions do not constitute barrier to access, but rather promote public health. Ultimately, the intention is to facilitate compliance of all stakeholders with the ethics and regulatory requirements of countries in the review and approval of clinical trials of medicines and vaccines as outlined in each country’s regulatory frameworks. | English | https://covid19crc.org/wp-content/uploads/2020/09/Regulatory_AVAREF_Guidance_2020.pdf | |
| CIOMS statement: Medicines assessment during public health emergencies needs good science, best practices and proper communication | Report / Publication | Regulatory | English | https://covid19crc.org/wp-content/uploads/2020/09/Regulatory_CIOMS_Statement_2020.pdf | ||
| Drug-induced liver injury (DILI): Current status and future directions for drug development and the post-market setting | Report / Publication | Regulatory | Drug-induced liver injury (DILI) is a growing challenge because of the ever- increasing number of drugs used in medical care. DILI is rare but can be serious and is largely unpredictable. It is an important cause of mortality and liver transplantation, and a leading cause of attrition in drug development. Progress is under way in identifying genetic risk factors, exploring new mechanistic concepts of the complex underlying interactions, and developing new biomarkers that can predict or diagnose DILI. The pharmaceutical industry has a key role in advancing these initiatives, and prospective DILI registries must adopt standard procedures for biological sample collection and storing. There is a strong need for standard guidelines to support these efforts. The consensus report of the CIOMS DILI Working Group aims to provide a critical framework and essential set of tools to detect, diagnose and manage DILI during drug development and in the post-marketing setting. The report is intended for clinical and basic pharmaceutical industry investigators who capture, analyze and communicate liver safety data in drug development. It is also intended for regulatory scientists and expert consultants who comprehensively evaluate new products and emerging biomarkers for their association with DILI risk, and for health care professionals who monitor and manage patients treated with potentially hepatotoxic drugs in clinical practice. | English | https://cioms.ch/publications/product/drug-induced-liver-injury/ | |
| Considerations for Regulatory Oversight of Clinical Trials in the COVID-19 Pandemic - PAHO | Report / Publication | Regulatory | This document provides national regulatory authorities (NRAs) with guidance for the regulation of clinical trials (CTs) in order to promote the investigation and use of safe and efficacious medicines and other health technologies that meet health needs during the COVID-19 pandemic. | English | https://iris.paho.org/handle/10665.2/52266 | |
| ICMRA statement on clinical trials | Report / Publication | Regulatory | The International Coalition of Medicines Regulatory Authorities (ICMRA) has pledged its collective support in countering the global COVID-19 pandemic | English | http://icmra.info/drupal/en/news/statement_on_clinical_trials | |
| ICMRA statement for healthcare professionals: How COVID-19 vaccines will be regulated for safety and effectiveness | Report / Publication | Regulatory | English | http://www.icmra.info/drupal/en/covid-19/vaccines_confidence_statement_for_hcps | ||
| Déclaration de l’ICMRA pour les professionnels de la santé : Comment l’innocuité et l’efficacité des vaccins contre la COVID-19 seront réglementées | Report / Publication | Regulatory | French | http://www.icmra.info/drupal/en/covid-19/vaccines_confidence_statement_for_hcps/french | ||
| Social Science in Humanitarian Action Platform | Website | Social Science | SSHAP (the Social Science in Humanitarian Action Platform) is a programme of work focusing on the social dimensions of emergency responses. We work on emergencies that relate to health, conflict or the environment. We focus our efforts on exploring the political economy, community engagement and cultural logics, social difference and vulnerabilities of those emergencies. SSHAP is a partnership between the Institute of Development Studies, Anthrologica and the London School of Hygiene and Tropical Medicine and is funded by the UK Foreign, Commonwealth and Development Office and the Wellcome Trust. It has previously received funding from UNICEF, and their images continue to be used on this website with their kind permission. Our vision is to encourage emergency responses which are effective, adaptive, contextually informed, sensitive to vulnerabilities and power relations, planned in consultation with affected communities and local institutions, and based on social and interdisciplinary science and evidence. With this in mind, one of our founding aims was to establish a network of social scientists with regional and subject expertise. This network is a driving force behind SSHAP’s work, rapidly providing insight, analysis and advice, tailored to demand and in accessible forms, to better design and implement the social and communication dimensions of emergency responses. | English | https://www.socialscienceinaction.org/ | |
| Sonar-Global | Website | Social Science | https://youtu.be/hb5oDb2AKUs | English | https://www.sonar-global.eu/ | |
| AViD Project on Facilitators and Barriers to Vaccine Deployment | Website | Social Science | Anthropological Exploration of Facilitators and Barriers to Vaccine Deployment and Administration During Disease Outbreaks | English | https://www.avidproject.co.uk/ | |
| COVID-19 vaccine development: Lessons learned from social science research and community engagement in clinical trials in low-resource settings | Webinar / Workshop recording | Social Science | Webinar organized by the Social Science Working Group featuring Dr David Kaawa-Mafigiri from Makerere University, Mr Kagisho Baepanye from the HIV Vaccine Trials Network (HVTN) and COVID-19 Prevention Network (CoVPN), Dr Luisa Enria from the London School of Hygiene and Tropical Medicine, Dr Primus Chi from KEMRI-Wellcome Trust Research Programme, and Dr Salla Sariola from the University of Helsinki. | English | https://covid19crc.org/videos/2021/covid-19-vaccine-development-lessons-learned-social-science-research-community-engagement-clinical-trials-low-resource-settings/ | |
| Operational experience for COVID-19 vaccine trials: Lessons from the field | Webinar / Workshop recording | Social Science | This webinar, the second in a series on social science research related to vaccine trials, brought together social science and community engagement experts to draw on their experiences from clinical trials during COVID-19 and past epidemics and discuss issues related to everyday ethical and practical challenges in community engagement work. | English | https://covid19crc.org/videos/2021/operational-experience-for-covid-19-vaccine-trials/ | |
| Applicability of COVID-19 vaccine trial results to low-and middle-income countries | Webinar / Workshop recording | Study Design and Analytics | Webinar featuring Dr Rebecca Kahn, Harvard University, Dr Rebecca Grais, Epicentre, France, Prof. Gagandeep Kang, Christian Medical College, Vellore, India & Steering Committee Member of the COVID-19 Clinical Research Coalition, and moderated by Dr James Watson, Mahidol Oxford Tropical Medicine Research Unit, UK & Co-Chair of the coalition’s Study Design & Analytics Working Group. | English | https://covid19crc.org/videos/2020/applicability-of-covid-19-vaccine-trial-results-to-low-and-middle-income-countries/ | |
| Efficient adaptive designs for clinical trials of interventions for COVID-19 | Guidance,Report / Publication | Study Design and Analytics | English | https://covid19crc.org/wp-content/uploads/2020/09/Stallard-Efficient-Adaptive-Designs-Clinical-Trials-Interventions-COVID19-StatBiopharmaRes-2020.pdf | ||
| GOST: A generic ordinal sequential trial design for a treatment trial in an emerging pandemic, PLOS Neglected Tropical Diseases 2017 | Guidance,Report / Publication | Study Design and Analytics | English | https://covid19crc.org/wp-content/uploads/2020/09/Whitehead-A-Generic-Ordinal-Sequential-Trial-Design-PLOSNTDs-2017.pdf | ||
| A minimal common outcome measure set for COVID-19 clinical research | Report / Publication | Study Design and Analytics | English | https://covid19crc.org/wp-content/uploads/2020/09/Marshall-Minimal-Common-Outcome-Measure-Set-COVID19-Clinical-Research-LancetInfectDis-2020.pdf | ||
| Resources for COVID-19 Randomized Clinical Trial Design | Website,Guidance | Study Design and Analytics | English | https://hbiostat.org/proj/covid19/ | ||
| Medical Product Quality Reports | Report / Publication | Supply and Market Dynamics; Medicine Quality | These monthly reports aim to collate information and reports in the public domain on the quality of medicinal products that are currently in use, or that are being trialled for COVID-19’s prevention or treatment. We do not aim to include discussion of the multiple fraudulent claims and quackery. We also include reports on key subjects such as access, affordability or off-label use for COVID-19 if they mention concern of the quality of the products. The reports presented were mostly extracted from the Medicines Quality Monitoring Globe (MQM Globe), a system that scrapes online newspapers (referenced in Google News) for early warnings of substandard and falsified medical products. The reports also include scientific literature and policy documents related to COVID-19 medical products quality identified by manual searches in PubMed and Google Scholar. | English | https://www.iddo.org/mq/research/medical-product-quality-reports | |
| Medicine Quality Monitoring Globe | Report / Publication | Supply and Market Dynamics; Medicine Quality | Current SF surveillance in most of the world is extremely limited and incidents relating to poor quality medicines are often not published in peer-reviewed scientific journals. The new Medicine Quality Monitoring (MQM) Globe helps fill evidence gaps with customised summaries of national and international newspaper reports on medical products’ quality viewable on-screen in French, Spanish, Mandarin, Vietnamese and English, and reports are available to download. The Globe also includes a new system for displaying regulatory and alerts webpages. These systems give early warning of new SF incidents, reveal the extent of the problem, how the media perceive and report cases, and may also shed light on how incidents can affect subsequent behaviours and perceptions. The MQM Globe supports national and international organisations to understand and raise awareness of the issue of substandard and falsified medicines. | English | https://www.iddo.org/medicine-quality-monitoring-globe | |
| Assessment of COVID-19 pandemic impact on illicit medication in East Africa | Report / Publication | Supply and Market Dynamics; Medicine Quality | English | https://enactafrica.org/research/interpol-reports/assessment-of-covid-19-pandemic-impact-on-illicit-medication-in-east-africa | ||
| Map of Bilateral COVID-19 Vaccine Purchases | Website,Report / Publication | Supply and Market Dynamics; Medicine Quality | Access to Covid-19 vaccines is an issue of high global public concern. We have been tracking publicly available data on agreements to manufacture, purchase, supply and/or donate Covid-19 vaccines in order to shed light on who is likely to have access to which vaccines, from whom, and when. | English | https://www.knowledgeportalia.org/covid19-vaccine-arrangements | |
| COVID-19 Diagnostics & Testing Hub – from the Foundation for Innovative New Diagnostics (FIND) | Website,Course / Training | "Virology, Immunology and Diagnostics" | English | https://www.finddx.org/covid-19/ | ||
| SARS-CoV-2 PCR training videos & supplementary materials — from the Robert Koch Institute | Website,Webinar / Workshop recording | "Virology, Immunology and Diagnostics" | English | https://zenodo.org/record/4058349#.YO6Ewegzabh | ||
| International Clinical Trials Registry Platform (ICTRP) | Website,Newsletter / Mailing list / email alert | Clinical Epidemiology,Clinical Management of COVID-19 in Resource-limited Settings,Clinical Pharmacology and Drug Candidates,Data Management,Data Sharing,Ethics,"Maternal, Newborn and Child Health",Regulatory,Social Science,Study Design and Analytics,Supply and Market Dynamics; Medicine Quality,"Virology, Immunology and Diagnostics",Vaccines,Therapeutics | About the WHO ICTRP Following the Ministerial Summit on Health Research that took place in Mexico City, Mexico, in November 2004, participants called for the WHO to facilitate the establishment of: "a network of international clinical trials registers to ensure a single point of access and the unambiguous identification of trials". This was further expanded on during the 58th World Health Assembly in Resolution WHA58.22 that called on the global scientific community, international partners, the private sector, civil society, and other relevant stakeholders to: "establish a voluntary platform to link clinical trials registers in order to ensure a single point of access and the unambiguous identification of trials with a view to enhancing access to information by patients, families, patient groups and others". Aims of the WHO ICTRP The main aim of the WHO ICTRP is to facilitate the prospective registration of the WHO Trial Registration Data Set on all clinical trials, and the public accessibility of that information. | English,Chinese,Dutch,German,Japanese,Korean,Persian,Peruvian,Portuguese,Spanish | https://www.who.int/clinical-trials-registry-platform | |
| The COVID-NMA initiative - A living mapping and living systematic review of Covid-19 trials | Website,Systematic Review | Clinical Epidemiology,Clinical Pharmacology and Drug Candidates,Clinical Management of COVID-19 in Resource-limited Settings,Data Management,Data Sharing,"Maternal, Newborn and Child Health",Ethics,Regulatory,Social Science,Study Design and Analytics,Supply and Market Dynamics; Medicine Quality,"Virology, Immunology and Diagnostics",Vaccines,Therapeutics | COVID-NMA is an international research initiative supported by the WHO and Cochrane. We provide a living mapping of COVID-19 trials. We are also conducting living evidence synthesis on preventive interventions, treatments and vaccines for COVID-19 to assist decision makers. | English | https://covid-nma.com/ | |
| Global Coronavirus COVID-19 Clinical Trial Tracker | Website | Clinical Epidemiology,Clinical Management of COVID-19 in Resource-limited Settings,Clinical Pharmacology and Drug Candidates,Data Management,Data Sharing,Ethics,"Maternal, Newborn and Child Health",Regulatory,Social Science,Study Design and Analytics,Supply and Market Dynamics; Medicine Quality,"Virology, Immunology and Diagnostics",Vaccines,Therapeutics | ) An interactive dashboard of clinical trials on COVID-19 that can be explored by type of product, trial status and country. | English | https://www.covid19-trials.com/ | |
| WHO ad hoc consultation COVID-19 therapeutics: Knowledge gaps and research priorities | Report / Publication | Clinical Pharmacology and Drug Candidates,Supply and Market Dynamics; Medicine Quality | Support materials COVID-19 therapeutics: Knowledge gaps and research priorities Over the past year, management of COVID-19 has greatly improved and mortality has been markedly reduced. Platforms have been rapidly established to evaluate potential therapeutics, initially focusing on repurposing of existing medicines. Some effective treatments have been identified and widely introduced. Despite these successes and the recent rollout of COVID-19 vaccines, new and improved therapeutics are still required. A WHO ad hoc consultation on 3rd March 2021, held under the umbrella of the WHO R&D Blueprint, sought to take stock of the current status of therapeutic development and to explore potential future directions of travel. | English | https://www.who.int/publications/m/item/who-ad-hoc-consultation-covid-19-therapeutics-knowledge-gaps-and-research-priorities | |
| Interactive Dashboards on COVID-19 testing policies and existing global capacity for COVID sequencing | Website | "Virology, Immunology and Diagnostics" | Attention policymakers and public health professionals: two new interactive dashboards are now available on our website! One is on COVID-19 testing policies, and the other on SARS-CoV-2 next-generation sequencing capacity | English | https://find.cmail19.com/t/ViewEmail/d/423F1FD0781D1ACD2540EF23F30FEDED/408DE43089AC96116E6039C17E42EE19 | |
| Covid-19 Maternal Immunization Tracker (COMIT) | Website | "Maternal, Newborn and Child Health" | As COVID-19 vaccines are being rolled out across the globe, many have wondered whether pregnant and lactating people can or should be vaccinated as part of broader immunization efforts. Countries have taken a variety of positions - ranging from highly restrictive policies that bar access to vaccines based on pregnancy or lactation status to widely permissive positions in which all pregnant or lactating people can receive vaccine, and in some cases, are recommended and encouraged to do so. The COVID-19 Maternal Immunization Tracker (COMIT) provides a global snapshot of public health policies that influence access to COVID-19 vaccines for pregnant and lactating people. Through maps, tables, and country profiles, COMIT provides regularly updated information on global and country level policies as they respond to the dynamic state of the pandemic and emerging evidence. | English | https://www.comitglobal.org/ | |
| PHEPREN: Ethics of research in pregnancy | Webinar / Workshop recording | "Maternal, Newborn and Child Health" | Recent evidence suggests that pregnant women are at a higher risk of morbidity and mortality from COVID-19, compared with age-matched women who are not pregnant. Yet the historical and systematic exclusion of pregnant women from research continues in the context of the COVID-19 pandemic, resulting in a lack of evidence for this population. How can pregnant women be ethically and safely included in research and what part should researchers play in this? What role is there for community engagement to reconcile cultural norms and beliefs with the ethical and clinical rationale for research during pregnancy? And how do current governance mechanisms and regulation help or hinder the inclusion of pregnant women in research? The 2016 Global Forum on Bioethics in Research (GFBR) meeting focused on the ethics of research in pregnancy. The full GFBR meeting report is available at this link. The proceedings and case studies are also available in Reproductive Health. This PHEPREN and GFBR seminar will reflect on the GFBR meeting conclusions and discuss if – and how – pregnant women are being included or excluded from COVID-19 research. | English | https://www.youtube.com/watch?v=sWCKbMXSmk8 | |
| Overview of Variants in Countries | Website | Clinical Epidemiology,Clinical Pharmacology and Drug Candidates,Data Management,Clinical Management of COVID-19 in Resource-limited Settings,Data Sharing,Ethics,"Maternal, Newborn and Child Health",Regulatory,Social Science,Study Design and Analytics,Supply and Market Dynamics; Medicine Quality,"Virology, Immunology and Diagnostics",Vaccines,Therapeutics | Graphs show for each country, the proportion of total number of sequences (not cases), over time, that fall into defined variant groups. Countries are displayed if they have at least 70 sequences in any variant being tracked. Countries are ordered by total number of sequences in tracked variants. The grey colour between the top of the coloured curve and '1' on the Y-axis is composed of variants that aren't currently tracked on CoVariants. Sequence counts are binned into 2-week intervals. It is worth interpreting with caution: Not all samples are representative - sometimes some samples are more likely to be sequenced than others (for containing a particular mutation, for example) The last data point - this often has incomplete data and may change as more sequences come in Frequencies that are very 'jagged' - this often indicates low sequencing numbers and so may not be truly representative of the country In many places, sampling may not be equal across the region: samples may only cover one area or certain areas. It's important not to assume frequencies shown are necessarily representative. | English | https://covariants.org/per-country | |
| Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21 | Report / Publication | "Maternal, Newborn and Child Health" | Abstract Background There is continuing public concern about the safety of COVID-19 vaccination during pregnancy. While there is no compelling biological reason to expect that mRNA COVID-19 vaccination (either preconception or during pregnancy) presents a risk to pregnancy, data are limited. It is, however, well documented that SARS-CoV-2 infection during pregnancy is associated with severe illness and increased risk of adverse pregnancy outcomes. Among recognized pregnancies in high-income countries, 11–16% end in spontaneous abortion (SAB). Methods People enrolled in v-safe, a voluntary smartphone-based surveillance system, who received a COVID-19 vaccine preconception or during pregnancy were contacted by telephone to enroll in the v-safe pregnancy registry. V-safe pregnancy registry participants who received at least one dose of an mRNA COVID-19 vaccine preconception or prior to 20 weeks’ gestation and who did not report a pregnancy loss before 6 completed weeks’ gestation were included in this analysis to assess the cumulative risk of SAB using Life Table methods. Results Among 2,456 pregnant persons who received an mRNA COVID-19 vaccine preconception or prior to 20 weeks’ gestation, the cumulative risk of SAB from 6–19 weeks’ gestation was 14.1% (95% CI: 12.1, 16.1%). Using direct age standardization to the selected reference population, the age-standardized cumulative risk of SAB was 12.8% (95% CI: 10.8–14.8%). Conclusions When compared to the expected range of SABs in recognized pregnancies, these data suggest receipt of an mRNA COVID-19 vaccine preconception or during pregnancy is not associated with an increased risk of SAB. These findings add to accumulating evidence that mRNA COVID-19 vaccines during pregnancy are safe. | English | https://www.researchsquare.com/article/rs-798175/v1 | |
| WHO consultation on COVID-19 vaccines research - 13 August 2021: Presentations and report | Guidance,Report / Publication | Vaccines | In continuation to the scientific discussions on COVID-19 vaccines research, WHO R&D Blueprint organized a consultation on the state of the art and best research methods to evaluate existing, modified and new COVID-19 vaccines. The objectives of this consultation was to review the available evidence on the efficacy and effectiveness of vaccines being deployed in terms of: - Emerging variants effect on protection levels - Duration of protection - Safety of booster vaccines - Research to evaluate various delivery strategies | English,French,Spanish,Arabic,Chinese,Russian | https://www.who.int/news-room/events/detail/2021/08/13/default-calendar/who-consultation-on-covid-19-vaccines-research-13-august-2021 | |
| COVID-19 Vaccines ViewHub | Website | Vaccines,Supply and Market Dynamics; Medicine Quality | VIEW-hub is an easy to use repository for the most relevant and recent vaccine data, covering topics such as Vaccine Introduction & Use, Immunization Equity, Vaccine Preventable Disease Burden, and Immunization System Strength. It also includes country level summary data on the latest academic studies on Vaccine Impact, as well as the Economic Burden of Disease. It now provides data on COVID. | English | https://view-hub.org/covid-19/?set=current-vaccine-intro-status&group=vaccine-introduction&category=covid | |
| Global research priorities for COVID-19 in maternal, reproductive and child health: Results of an international survey | Report / Publication | "Maternal, Newborn and Child Health" | Background The World Health Organization’s “Coordinated Global Research Roadmap: 2019 Novel Coronavirus” outlined the need for research that focuses on the impact of COVID-19 on pregnant women and children. More than one year after the first reported case significant knowledge gaps remain, highlighting the need for a coordinated approach. To address this need, the Maternal, Newborn and Child Health Working Group (MNCH WG) of the COVID-19 Clinical Research Coalition conducted an international survey to identify global research priorities for COVID-19 in maternal, reproductive and child health. Method This project was undertaken using a modified Delphi method. An electronic questionnaire was disseminated to clinicians and researchers in three different languages (English, French and Spanish) via MNCH WG affiliated networks. Respondents were asked to select the five most urgent research priorities among a list of 17 identified by the MNCH WG. Analysis of questionnaire data was undertaken to identify key similarities and differences among respondents according to questionnaire language, location and specialty. Following elimination of the seven lowest ranking priorities, the questionnaire was recirculated to the original pool of respondents. Thematic analysis of final questionnaire data was undertaken by the MNCH WG from which four priority research themes emerged. Results Questionnaire 1 was completed by 225 respondents from 29 countries. Questionnaire 2 was returned by 49 respondents. The four priority research themes which emerged from the analysis were 1) access to healthcare during the COVID-19 pandemic, 2) the direct and 3) indirect effects of COVID-19 on pregnant and breastfeeding women and children and 4) the transmission of COVID-19 and protection from infection. Conclusion The results of these questionnaires indicated a high level of concordance among continents and specialties regarding priority research themes. This prioritized list of research uncertainties, developed to specifically highlight the most urgent clinical needs as perceived by healthcare professionals and researchers, could help funding organizations and researchers to answer the most pressing questions for clinicians and public health professionals during the pandemic. It is hoped that these identified priority research themes can help focus the discussion regarding the allocation of limited resources to enhance COVID-19 research in MNCH globally. | English | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257516#abstract0 | |
| General Considerations for Clinical Studies E8 (R1), International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use | Guidance | Clinical Pharmacology and Drug Candidates,Regulatory,Study Design and Analytics | English | https://www.ema.europa.eu/en/ich-e8-general-considerations-clinical-studies | ||
| Perspective: Integrating Research into Community Practice – Toward Increased Diversity in Clinical Trials | Report / Publication | Ethics,Social Science | English | https://www.nejm.org/doi/full/10.1056/NEJMp2107331 | ||
| COVID-19 vaccine trials with children: ethics pointers | Report / Publication | "Maternal, Newborn and Child Health",Ethics | As healthcare authorities around the world strive to get as many citizens as possible vaccinated against the SAR-CoV-2 virus, many countries have begun including children in the population groups to be vaccinated. Properly designed clinical trials involving children are important to ensure safety, efficacy, and dosage of therapies in (developing) children. Within the complex health, social, and political scenario of the ongoing pandemic, ethics committees and policy makers in low-income and middle-income settings need to consider additional ethical questions when called on to review phase III COVID-19 vaccine trials involving in children. We set out some of the ethical questions to keep in mind before, during, and after the implementation of phase III COVID-19 vaccine trials in limited resource settings. Specifically, we discuss and offer succinct answers to the following questions: How relevant will the trial vaccine be for the population participating in the trial? Should vaccines that have not been approved for use among adults be approved for use in trials with children? Which children should be involved in COVID-19 vaccine trials? What criteria of informed consent are to be adopted with minors? Placebo versus an existing already approved vaccine? What specific duties of ancillary care should be taken into consideration for COVID-19 vaccines especially in low-income and middle-income countries? The answers we offer are considerations that can serve as ‘things to think about’ when reviewing or implementing COVID-19 trials involving children in low-income settings. | English | https://gh.bmj.com/content/7/1/e007466 | |
| Guideline on registry-based studies | Guidance | Regulatory | The objective of this Guideline is to provide recommendations on key methodological aspects that are specific to the use of patient registries by marketing authorisation applicants and holders (MAAs/MAHs) planning to conduct registry-based studies. To support these recommendations, considerations and aspects of patient registries that NCAs and EMA view important as good regulatory practice in registry-based studies are included in the Annex. | English | guideline-registry-based-studies_en-0.pdf (https://v5.airtableusercontent.com/v3/u/49/49/1767859200000/y3FaJKF4wrA04WriDtpgKw/3lZkVUsCJEe26lMmq_LzQ-uXGGiip-ApoIsFdx5jgg_WtgYbYsdX8mzghsM9sKMG7pBgqAtAH8ZwSG7JnjBb32kv0PIA1Ny9LMjz4gJQtFYH6fLtTqrTUuyh4a3m9altkmEn0X4SauDNlnNRAAR6-uw19QjrTytUg5guzc3shoFheqMPogk1dVBITySKocXn/ttWNytzZacsoVr9MsTyULzQPz_P8xhalnZFa0GJFxao) | |
| COVID-19 in pregnancy, delivery and the neonatal period | Course / Training | "Maternal, Newborn and Child Health" | Although it was generally believed that pregnant women with COVID-19 were at similar risk to the general population, the available data were limited and mainly from small case series without controls, which could not answer fundamental questions relating to the effects of the disease in pregnancy. In order to provide women, families, health care providers and policymakers with prompt, much needed high-quality evidence regarding the effects of COVID-19 on maternal, fetal and neonatal outcomes, INTERCOVID conducted a large, multi-national, prospective cohort study with the aim of assessing the effect of COVID-19 in pregnancy on maternal, fetal and neonatal outcomes worldwide. You can read the results here (Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study). The information from the study will help to optimise maternal and newborn care, inform decision-making about the allocation of resources, and guide the process toward social adaptation. The study is coordinated by the INTERGROWTH-21st Team at the University of Oxford. COVID-19 in pregnancy, delivery and the neonatal period, interactive e-Learning course About the development of this course As a complement to the study, the development of this course was motivated by the commitment of the INTERGROWTH-21st Consortium to improve maternal and perinatal health globally. This training course is a practical interactive package targeted at health professionals caring for pregnant women and their newborns. The aim of the course is to provide healthcare providers with evidence-based recommendations for disease prevention and management of pregnant women and their babies during the COVID-19 pandemic and thereby lessen the adverse maternal and newborn outcomes from the disease. The content of this course is based on the information available as at April 2021. Any new developments that require updating will be done periodically. | English | https://globalhealthtrainingcentre.tghn.org/intergrowth-21st-course-covid-19-pregnancy-delivery-and-neonatal-period/ | |
| COVID-19 therapeutics tracker | Systematic Review | Therapeutics | A handful of therapeutics have been approved specifically to treat COVID-19, reduce its severity, or prevent it entirely. Among those treatments are dexamethasone, Avigan (favilavir), Veklury (remdesivir) alone and in combination with Olumiant (baricitinib), Lagevrio (molnupiravir), Xevudy (sotrovimab), Regkirona (regdanvimab), Ronapreve (casirivimab and imdevimab), amubarvimab and romlusevimab (formerly BRII-196 and BRII-198), Actemra/RoActemra (tocilizumab), Paxlovid (nirmatrelvir + ritonavir), and Kineret (anakinra). Evusheld (tixagevimab and cilgavimab; AZD7442) has been authorized in several countries for use as pre-exposure prophylaxis. Regulators around the world have allowed additional treatments to be used on an emergency-use basis. A key focus in 2022 will be the efficacy of therapeutics against current and emergent SARS-CoV-2 variants. Therapeutics that are effective against one version of the virus, for example, may be significantly less effective or even ineffective against a new variant. Whenever possible, we will describe how these therapeutics work against the dominant variants circulating throughout the world. This tracker will be updated biweekly with the latest in developments for treatment candidates who have advanced to at least Phase 1 study. If you notice an issue with this data or wish to submit an update, please email Regulatory Focus at news@raps.org. | English | https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker | |
| WHO guidelines and resources on Therapeutics & COVID-19 | Website,Guidance | Therapeutics | WHO develops the most up-to-date clinical practice guidelines for the use of therapeutics for patients with COVID-19 based on ongoing assessment of new evidence generated by the international medical research community and first responders. Guidelines and resources on this page include: - Information on COVID-19 therapeutics under assessment by WHO and current timelines for the development of clinical practice guidelines. - The most recent WHO guideline for therapeutics to treat COVID-19 and associated online interactive publication platform. - Open-access journal publications for the current therapeutic recommendations. - Resources and tools for health care workers to support prescribing and administering therapeutics and monitoring patients. - Resources for patients, caregivers and families. | English | https://www.who.int/teams/health-care-readiness/covid-19/therapeutics | |
| ACT-Accelerator Therapeutics Partnership - COVID-19 Therapeutics Investment Case | Report / Publication | Therapeutics | English | https://unitaid.org/assets/Therapeutics-Partnership-Investment-Case.pdf | ||
| COVID-19 therapeutics in resource-constrained settings: Where are we and what do we need? | Webinar / Workshop recording | Therapeutics | To date, the few medications with proven effectiveness in COVID-19 are appropriate primarily for the treatment of severely ill, hospitalized patients in well-resourced healthcare settings. WHO recommends the use of monoclonal antibody treatment for people with early-stage COVID-19, but these treatments too are expensive and complex to use in resource-constrained settings. No proven medications for uncomplicated COVID-19 are widely available in low- and middle-income countries. So where are we today with new and emerging therapeutics that would be both effective and affordable in preventing the progression of mild or moderate COVID-19 and thereby prevent hospitalization? A couple of promising treatments have emerged recently, with early efforts underway to make these drugs more available than COVID-19 vaccines have been. What are the current research priorities, and do current efforts meet the needs? | English | https://www.youtube.com/watch?v=aBlY4RuUSsQ |
Join CERCLE
We are looking for dedicated individuals and institutions who are eager to contribute their expertise and commitment to fast-track research in infectious diseases with potential for epidemics and pandemics, as well as antimicrobial resistance (AMR), specific to low-resource settings.